Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MPO | P05164 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | ECE1 | P42892 | 12/20 | 0.55 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.54 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.54 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30665628 | 0.95 | KISS1R (0.55) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL29429568 | 0.94 | ACE (0.67) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL31039952 | 0.92 | ACE (0.64) | ACEECE1MAGI3ERAP2 | |
| SCHEMBL21641803 | 0.91 | KDM4E (0.68) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL5583835 | 0.91 | KDM4E (0.68) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL31454970 | 0.89 | KDM4E (0.60) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL29377160 | 0.89 | ACE (0.62) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL21641797 | 0.89 | KDM4E (0.65) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL29384133 | 0.89 | KDM4E (0.65) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL8525833 | 0.89 | KDM4E (0.65) | ACEKDM4EMEN1LMNAMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11976124-B2 | Monoclonal antibodies activating CD40 and uses thereof | ABVISION, INC. (US) | 2024-05-07 | — | — | US | claimed |
| EP-4678664-A2 | ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODY PERMEATING BLOOD-BRAIN BARRIER | JCR Pharmaceuticals Co., Ltd. (JP) | 2026-01-14 | — | — | EP | disclosed |
| EP-3315606-B1 | ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODY PERMEATING BLOOD-BRAIN BARRIER | JAPAN CHEM RES (JP) | 2025-11-26 | — | — | EP | disclosed |
| US-20240262926-A1 | Fusion Protein Containing BDNF | JCR PHARMACEUTICALS CO., LTD. (JP) | 2024-08-08 | — | — | US | disclosed |
| US-11976124-B2 | Monoclonal antibodies activating CD40 and uses thereof | ABVISION, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-11958905-B2 | Fusion proteins containing a BDNF and an anti-human transferrin receptor antibody | JCR PHARMACEUTICALS CO., LTD. (JP) | 2024-04-16 | — | — | US | disclosed |
| CN-114409783-A | Anti-human transferrin receptor antibodies across the blood brain barrier | JCR制药股份有限公司 | 2022-04-29 | — | — | CN | disclosed |
| US-20220064288-A1 | Anti-Human Transferrin Receptor Antibody Permeating Blood-Brain Barrier | JCR PHARMACEUTICALS CO., LTD. (JP) | 2022-03-03 | — | — | US | disclosed |
| US-11248045-B2 | Anti-human transferrin receptor antibody permeating blood-brain barrier | JCR PHARMACEUTICALS CO., LTD. (JP) | 2022-02-15 | — | — | US | disclosed |